Market Research Industry Today
Non-invasive Prenatal Testing Market to Reach USD 13.2 Billion by 2035, Driven by Rising Maternal Age and Demand for Safer Prenatal Screening - TMR
The global non-invasive prenatal testing market was valued at approximately US$4.7 billion in 2024 and is projected to grow at a CAGR of 9.5% from 2025 to 2035, reaching approximately US$13.2 billion by the end of 2035. Market expansion is being driven by the increasing prevalence and detection of chromosomal abnormalities, rising maternal age, and growing preference for safe and accurate prenatal screening technologies.
Non-invasive prenatal testing, commonly known as NIPT, is increasingly being adopted as an important screening option because it analyzes cell-free fetal DNA circulating in maternal blood without requiring an invasive procedure. Advances in DNA sequencing and molecular analysis are improving the ability of NIPT platforms to screen for a range of chromosomal abnormalities at an early stage of pregnancy.
Discover essential conclusions and data from our Report in this sample -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=374
Market Overview
NIPT is a prenatal screening method used to assess the risk of certain genetic and chromosomal conditions in a fetus. The test analyzes small fragments of fetal DNA present in the mother's blood and can generally be performed from around the tenth week of pregnancy. Unlike invasive procedures such as amniocentesis and chorionic villus sampling, NIPT requires only a maternal blood sample and does not involve direct physical intervention with the fetus.
The technology is primarily used to screen for chromosomal conditions including Down syndrome, Edwards syndrome, and Patau syndrome. Depending on the test, it can also provide information related to sex chromosome abnormalities and fetal sex. Growing awareness of prenatal screening options, improvements in genomic technologies, and increasing demand for earlier assessment of chromosomal abnormalities are supporting market growth.
Healthcare professionals and expectant parents are increasingly considering DNA-based screening methods because of their non-invasive nature and high screening performance. At the same time, growing investment by diagnostic laboratories, biotechnology companies, and healthcare providers is expanding the availability of NIPT services across developed and emerging markets.
Key Market Growth Drivers
Rising Prevalence of Down Syndrome Cases
The growing prevalence and detection of Down syndrome and other chromosomal abnormalities are expected to contribute significantly to demand for NIPT. Conventional screening methods, including nuchal translucency scans and maternal serum screening, are non-invasive but have limitations in screening accuracy. Invasive diagnostic procedures such as amniocentesis and chorionic villus sampling can provide definitive diagnostic information but involve procedural risks, which can influence patient and physician preferences.
NIPT provides an alternative screening approach by analyzing cell-free fetal DNA obtained from maternal blood. This has contributed to the adoption of tests designed to assess the likelihood of trisomy 21, trisomy 18, trisomy 13, and certain sex chromosome abnormalities.
According to information cited from Down Syndrome Education International, the prevalence of Down syndrome varies considerably across countries, ranging from approximately 1 in 1,500 to 1 in 400 births, with an estimated 220,000 babies born with Down syndrome globally each year. The Centers for Disease Control and Prevention has reported an incidence of approximately 1 in 700 births in the U.S. Such prevalence patterns contribute to continued demand for accessible prenatal screening technologies.
Growing Maternal Age and Associated Chromosomal Risks
Increasing maternal age is another important factor supporting NIPT adoption. The average age at first pregnancy has increased in several developed countries, influenced by factors including education, financial considerations, career development, and changing social patterns. Advanced maternal age is associated with an increased risk of fetal chromosomal abnormalities, thereby increasing the importance of prenatal screening.
According to data cited from the American Academy of Family Physicians, the risk of fetal chromosomal abnormalities increases with maternal age, particularly after age 30. The cited estimates indicate that the probability of Down syndrome rises from approximately 1 in 1,300 among pregnant women up to age 25 to approximately 1 in 365 at age 35 and approximately 1 in 30 after age 40.
The changing maternal age profile is consequently creating greater demand for screening technologies capable of providing early risk assessment without the procedural risks associated with invasive testing. This trend is expected to remain an important contributor to the NIPT market throughout the forecast period.
Diagnostic Laboratories Segment to Expand Rapidly
Based on end user, the global non-invasive prenatal testing market is segmented into hospitals, specialty clinics, diagnostic laboratories, and other users such as research institutes. The diagnostic laboratories segment is expected to expand at a significant rate during the forecast period, supported by expanding diagnostic infrastructure and the increasing availability of specialized NIPT services.
The growing number of laboratories offering prenatal genetic screening is improving access to NIPT and broadening the range of tests available to healthcare professionals and patients. For instance, MedGenome Labs Ltd. offers the MedGenome Claria NIPT test for screening trisomies 21, 18, and 13, along with monosomy X and other sex chromosome abnormalities.
MedGenome's Claria NIPT Plus is designed to screen for a broader range of conditions, including Down syndrome, Edwards syndrome, Patau syndrome, triploidy, Turner syndrome, Klinefelter syndrome, Triple X syndrome, Jacob's syndrome, 22q11.2 deletion syndrome, 1p36 deletion syndrome, Prader-Willi syndrome, Angelman syndrome, and Cri-du-chat syndrome. Such expanded testing capabilities are supporting the development of diagnostic laboratories as important service providers in the NIPT ecosystem.
Regional Outlook
North America dominated the global non-invasive prenatal testing market in 2024, accounting for approximately 60% of the market share, followed by Europe. The region's leading position is supported by its advanced healthcare infrastructure, high levels of prenatal screening, strong adoption of genomic technologies, and presence of major companies operating in the prenatal testing market.
The U.S. represents a particularly important market because of its established diagnostic infrastructure and extensive availability of NIPT services. Continued development of cell-free DNA testing is also expanding the scope of prenatal screening. In May 2024, Natera introduced a cell-free DNA-based fetal RhD test, providing a non-invasive method for determining fetal RhD status from maternal blood as early as nine weeks of gestation. The test achieved 100% sensitivity and more than 99% specificity in a validation study involving more than 650 RhD-negative pregnancies.
Meanwhile, Asia Pacific is projected to record the fastest CAGR during the forecast period. Rising maternal age, increasing awareness of prenatal screening, improvements in healthcare infrastructure, and growing adoption of next-generation sequencing technologies are contributing to regional market development. Countries such as China and Japan are making significant advances in genomic medicine and diagnostic technologies, creating favorable conditions for NIPT adoption across the region.
Analysis of Key Players – Key Player Strategies
The non-invasive prenatal testing market features a relatively consolidated competitive landscape, with major companies leveraging broad product portfolios, established distribution networks, technological expertise, and strategic collaborations to strengthen their positions. Companies are focusing on expanding test menus, improving genomic analysis capabilities, increasing testing accessibility, and developing specialized screening applications.
Key companies profiled in the market include Berry Genetics, BGI, Laboratory Corporation of America Holdings, Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., Natera, Inc., PerkinElmer Inc., Eurofins Scientific, and Igenomix, along with other prominent market participants.
Access our report for a comprehensive look at key insights -
https://www.transparencymarketresearch.com/noninvasive-prenatal-diagnostics-market.html
Market Challenges & Opportunities
Despite strong growth prospects, the NIPT market faces challenges related to test costs, reimbursement policies, regulatory requirements, availability of genetic counseling, and differences in screening practices across countries. NIPT is also a screening rather than a definitive diagnostic test, making appropriate clinical interpretation and, where indicated, confirmatory diagnostic testing important considerations.
At the same time, the market presents significant opportunities through the expansion of testing panels, improvements in sequencing technologies, increased adoption in emerging economies, and development of tests for additional genetic and fetal conditions. Growing awareness of prenatal genetic screening and increasing availability of specialized diagnostic laboratories are also creating opportunities for market participants.
Key Player Strategies
Leading companies are pursuing product launches, partnerships, technological development, and expansion of testing capabilities to respond to increasing demand for non-invasive prenatal screening. Companies are increasingly focusing on improving turnaround times, expanding the range of detectable abnormalities, and developing tests that address specific clinical requirements.
In February 2025, Yourgene Health, part of the Novacyt group, announced the launch of IONA Care+ in the U.K. The service uses Yourgene's IONA Nx NIPT workflow to provide non-invasive prenatal testing and is intended to reduce reliance on invasive procedures where appropriate while providing screening results to expectant parents.
In May 2024, Natera, Inc. announced the launch of its new cell-free DNA-based fetal RhD test. The test can be performed from nine weeks of gestation and determines fetal RhD status from maternal blood, including complex pseudogene and RhD-CE-D hybrid variants. The development expands the potential applications of cell-free DNA analysis beyond conventional aneuploidy screening.
Investment Landscape and ROI Outlook
The investment landscape for NIPT is supported by growing demand for genomic diagnostics, rising healthcare expenditure, increasing maternal age, and continued advances in molecular testing technologies. Diagnostic laboratories, biotechnology companies, and healthcare providers are investing in sequencing platforms, laboratory infrastructure, testing services, and data-analysis capabilities to address growing prenatal screening requirements.
The projected expansion of the market from US$4.7 billion in 2024 to US$13.2 billion by 2035 indicates substantial opportunities across instruments, kits and reagents, testing services, and technology platforms. Continued development of whole-genome sequencing, SNP analysis, microarray analysis, and rolling circle amplification technologies is expected to broaden the capabilities and applications of prenatal genetic screening.
Market Segmentations
The non-invasive prenatal testing market is segmented by test type into cell-free DNA screening tests, serum marker screening tests, neural tube defects tests, and ultrasonography. By product, the market includes instruments as well as kits and reagents. Based on technology, the market is categorized into whole-genome sequencing, SNP analysis, microarray analysis, and rolling circle amplification.
By indication, the market includes Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), Turner syndrome (monosomy X/XO), Klinefelter syndrome (XXY), Jacob's syndrome (XYY), gender identification, and other conditions such as Triple X syndrome. By end user, the market is divided into hospitals, specialty clinics, diagnostic laboratories, and other users such as research institutes.
Geographically, the market covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Key countries covered include the U.S., Canada, Germany, the U.K., France, Italy, Spain, China, India, Japan, Australia & New Zealand, Brazil, Mexico, GCC countries, and South Africa.
Why Buy This Report?
The non-invasive prenatal testing market report provides comprehensive analysis of market size, growth trends, competitive dynamics, technological developments, and regional opportunities through 2035. The study includes global and regional segment analysis, along with qualitative assessment of market drivers, restraints, opportunities, emerging trends, and developments within the parent industry.
The report also provides a detailed assessment of leading companies, including their product portfolios, sales footprints, key subsidiaries or distributors, business strategies, recent developments, and financial information. The report is available in Electronic PDF and Excel formats, providing market intelligence for business planning, competitive analysis, product strategy, and investment evaluation.
FAQs
What is the projected size of the non-invasive prenatal testing market by 2035? The global non-invasive prenatal testing market is projected to reach approximately US$13.2 billion by 2035, rising from US$4.7 billion in 2024.
What is the expected CAGR of the NIPT market? The market is estimated to grow at a CAGR of 9.5% between 2025 and 2035.
What are the major factors driving the NIPT market? Key growth drivers include the rising prevalence and detection of chromosomal abnormalities, increasing maternal age and associated chromosomal risks, growing demand for non-invasive screening, advances in genomic technologies, and expanding prenatal diagnostic infrastructure.
Which region dominates the non-invasive prenatal testing market? North America dominated the market in 2024, accounting for approximately 60% of the global market share, supported by advanced healthcare infrastructure, high adoption of prenatal screening technologies, and the presence of major industry participants.
Who are the key players in the non-invasive prenatal testing market? Major companies include Berry Genetics, BGI, Laboratory Corporation of America Holdings, Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., Natera, Inc., PerkinElmer Inc., Eurofins Scientific, and Igenomix, along with other prominent market participants.
Buy this Premium Research Report for expert-driven insights and conclusions -
https://www.transparencymarketresearch.com/checkout.php?rep_id=374<ype=S
More Trending Reports by Transparency Market Research -
GCC Countries Vertical Lift Module Market
Computed Tomography (CT) Market
Atomic Force Microscopes (AFM) Market
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com
Share on Social Media
Contact Information
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street,
Suite 700
Albany NY
New York
12207
+1-518-618-1030
https://www.transparencymarketresearch.com
Other Industry News
Ready to start publishing
Sign Up today!
